K.J. Harrison & Partners Inc Invests $1.76 Million in Illumina, Inc. $ILMN

K.J. Harrison & Partners Inc acquired a new stake in Illumina, Inc. (NASDAQ:ILMN) during the second quarter, HoldingsChannel reports. The firm acquired 10,000 shares of the life sciences company’s stock, valued at approximately $1,758,000.

Several other hedge funds and other institutional investors have also made changes to their positions in ILMN. Elyxium Wealth LLC purchased a new position in Illumina in the fourth quarter valued at approximately $25,000. TD Waterhouse Canada Inc. purchased a new stake in shares of Illumina during the 4th quarter worth approximately $26,000. Laurel Wealth Advisors LLC acquired a new position in shares of Illumina in the 4th quarter valued at $26,000. Activest Wealth Management grew its position in shares of Illumina by 671.9% in the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock valued at $32,000 after buying an additional 215 shares during the last quarter. Finally, Quarry LP purchased a new position in shares of Illumina in the 3rd quarter valued at $32,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Up 1.2%

ILMN stock opened at $193.13 on Tuesday. The company has a fifty day moving average price of $184.48 and a 200 day moving average price of $150.83. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $207.00. The company has a market cap of $29.16 billion, a price-to-earnings ratio of 36.03, a price-to-earnings-growth ratio of 2.69 and a beta of 1.45. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same period in the previous year, the business posted $1.19 earnings per share. Illumina’s quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Sell-side analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ILMN. Deutsche Bank Aktiengesellschaft cut shares of Illumina to a “hold” rating in a research report on Wednesday, August 5th. Royal Bank Of Canada raised their price objective on Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Piper Sandler reiterated an “overweight” rating and set a $225.00 target price (up from $200.00) on shares of Illumina in a research report on Monday, August 3rd. Leerink Partners boosted their target price on Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a report on Friday, July 17th. Finally, Zacks Research raised Illumina from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $188.40.

Insider Buying and Selling

In other Illumina news, Director Keith A. Meister sold 283,269 shares of Illumina stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $199.61, for a total value of $56,543,325.09. Following the transaction, the director directly owned 2,089,425 shares in the company, valued at approximately $417,070,124.25. This trade represents a 11.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the transaction, the senior vice president owned 21,259 shares in the company, valued at $3,456,500.81. This trade represents a 3.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,415,351 shares of company stock valued at $255,966,311 over the last 90 days. Insiders own 2.90% of the company’s stock.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.